Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Kitagawa S, Zenke Y, Taki T, Aokage K, Sakai T, Shibata Y, Izumi H, Nosaki K, Umemura S, Matsumoto S, Yoh K, Sakamoto N, Sakashita S, Kojima M, Tsuboi M, Goto K, Ishii G.
Kitagawa S, et al. Among authors: sakashita s.
Lung Cancer. 2024 Feb;188:107453. doi: 10.1016/j.lungcan.2023.107453. Epub 2023 Dec 30.
Lung Cancer. 2024.
PMID: 38160515